​

Summit Therapeutics Ownership | Who Owns Summit Therapeutics?

OverviewForecastFinancialsChartTranscripts

Summit Therapeutics Ownership Summary

Summit Therapeutics is owned by 3.56% institutional investors, 84.31% insiders, and 12.13% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 3.31% of SMMT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 0.48% of its assets in Summit Therapeutics shares.

SMMT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockSummit Therapeutics3.56%84.31%12.13%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Baker bros. advisors lp24.42M3.31%$471.16M
Vanguard group11.67M1.61%$208.26M
Blackrock funding, inc. /de8.43M1.16%$150.46M
Blackrock7.90M1.13%$61.61M
Fmr8.06M1.11%$143.75M
Price t rowe associates inc /md/6.56M0.90%$117.00M
State street4.12M0.59%$32.16M
Geode capital management3.20M0.44%$57.13M
Charles schwab investment management1.49M0.20%$26.50M
Pictet asset management sa1.39M0.19%$24.76M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Baker bros. advisors lp24.42M5.21%$471.16M
Cutter capital management, lp400.00K3.36%$7.72M
Superstring capital management lp164.56K2.54%$2.94M
Ivyrock asset management (hk)166.50K1.31%$2.97M
Sectoral asset management69.24K1.04%$1.34M
Wealth management partners97.38K0.75%$1.74M
Rock springs capital management lp1.05M0.72%$18.81M
Jgp global gestao de recursos ltda.17.08K0.69%$304.79M
Qvt financial lp360.52K0.64%$6.95M
Healthinvest partners ab101.18K0.62%$1.31M

Top Buyers

HolderShares% AssetsChange
Price t rowe associates inc /md/6.56M0.01%1.12M
Ubs group1.19M0.00%1.07M
Vanguard group11.67M0.00%724.04K
Pictet asset management sa1.39M0.03%695.84K
Caption management499.10K0.06%499.10K

Top Sellers

HolderShares% AssetsChange
State street4.12M0.00%-3.99M
Blackrock7.90M0.00%-1.92M
Millennium management887.01K0.01%-1.16M
Darwin global management---1.08M
Anson funds management lp---941.91K

New Positions

HolderShares% AssetsChangeValue
Caption management499.10K0.06%499.10K$3.89M
Bnp paribas arbitrage, snc493.19K0.00%493.19K$8.80M
Cutter capital management, lp400.00K3.36%400.00K$7.72M
Ivyrock asset management (hk)166.50K1.31%166.50K$2.97M
Superstring capital management lp164.56K2.54%164.56K$2.94M

Sold Out

HolderChange
Citadel advisors-5.00
Geowealth management-14.00
Signaturefd-21.00
Capital performance advisors llp-36.00
Amundi-58.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202514-93.83%26,286,219-71.60%32.20%7-95.17%2-94.74%
Dec 31, 20242089.47%86,084,9161.94%118.77%13112.93%3911.43%
Sep 30, 202418943.18%84,448,62517.02%1111.18%11579.69%35-23.91%
Jun 30, 202413123.58%72,166,50145.37%1016.02%6410.34%4573.08%
Mar 31, 20241069.28%49,642,03954.58%837.82%5828.89%2636.84%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.55M0.48%52.99K
Vanguard US Total Market Shares ETF3.43M0.46%-167.64K
Vanguard Small Cap Index2.78M0.37%19.69K
SPDR® S&P Biotech ETF2.59M0.35%3.35K
iShares Russell 2000 ETF2.36M0.32%1.16K
Fidelity Growth Compy Commingled Pl S2.29M0.31%142.50K
Fidelity Select Biotechnology2.25M0.30%-41.30K
Vanguard Institutional Extnd Mkt Idx Tr2.17M0.29%11.89K
Vanguard Small Cap Value Index Inv1.80M0.24%5.67K
Fidelity Growth Company Fund1.78M0.24%108.80K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 27, 2024Zanganeh Mahkam Chief Executive OfficerBuy$127.67K
Mar 27, 2024Zanganeh Mahkam Chief Executive OfficerBuy$74.20K
Mar 26, 2024Zanganeh Mahkam Chief Executive OfficerBuy$112.50K
Mar 27, 2024Zanganeh Mahkam Chief Executive OfficerBuy$96.72K
Mar 26, 2024Dhingra Ankur Chief Financial OfficerBuy$375.00K

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1--
2024 Q4--
2024 Q3--
2024 Q2--

SMMT Ownership FAQ

Who Owns Summit Therapeutics?

Summit Therapeutics shareholders are primarily institutional investors at 3.56%, followed by 84.31% insiders and 12.13% retail investors. The average institutional ownership in Summit Therapeutics's industry, Biotech Stocks , is 63.96%, which Summit Therapeutics falls below.

Who owns the most shares of Summit Therapeutics?

Summit Therapeutics’s largest shareholders are Baker bros. advisors lp (24.42M shares, 3.31%), Vanguard group (11.67M shares, 1.61%), and Blackrock funding, inc. /de (8.43M shares, 1.16%). Together, they hold 6.08% of Summit Therapeutics’s total shares outstanding.

Does Blackrock own Summit Therapeutics?

Yes, BlackRock owns 1.13% of Summit Therapeutics, totaling 7.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.61M$. In the last quarter, BlackRock decreased its holdings by -1.925M shares, a -19.59% change.

Who is Summit Therapeutics’s biggest shareholder by percentage of total assets invested?

Baker bros. advisors lp is Summit Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.21% of its assets in 24.42M Summit Therapeutics shares, valued at 471.16M$.

Who is the top mutual fund holder of Summit Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Summit Therapeutics shares, with 0.48% of its total shares outstanding invested in 3.55M Summit Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools